Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

BACKGROUND: SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Ferrante, Shannon Allen, Chhatwal, Jagpreet, Brass, Clifford A, El Khoury, Antoine C, Poordad, Fred, Bronowicki, Jean-Pierre, Elbasha, Elamin H
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2013
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3643851/
https://ncbi.nlm.nih.gov/pubmed/23621902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-13-190
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia